Systematic review of spontaneous reports of myocarditis and pericarditis in transplant
recipients and immunocompromised patients following COVID-19 mRNA vaccination

Samantha Lane*

[1]Drug Safety Research Unit, Southampton, UK

[2]School of Pharmacy & Biomedical Sciences, University of Portsmouth, UK

ORCID ID: 0000-0001-7532-1149

Alison Yeomans

[1]Drug Safety Research Unit, Southampton, UK

Saad Shakir

[1]Drug Safety Research Unit, Southampton, UK

[2]School of Pharmacy & Biomedical Sciences, University of Portsmouth, UK

*Correspondence to: Miss Samantha Lane

Drug Safety Research Unit, Bursledon Hall, Blundell Lane, Southampton, Hampshire, UK,
SO31 1AA

Samantha.Lane@dsru.org

Word count: 5,474 (including subheadings and methods)

Number of tables: 6

Number of figures: 4

Abstract

Objectives: To determine whether spontaneous reporting rates of myocarditis and
pericarditis differed in immunocompromised patients compared to the whole population
overall, and in terms of demographics, vaccine dose, and time-to-onset.

Design: Systematic review of spontaneously reported data from the European
Union/European Economic Area (EU/EEA), the United States (US) and the United Kingdom
(UK).

Data Sources: EudraVigilance (EU/EEA), Vaccine Adverse Event Reporting System (VAERS;
US) and the Medicines and Healthcare products Regulatory Agency (MRHA, UK)
spontaneous reporting databases were searched from date of vaccine launch to 01
December 2021.

Eligibility criteria: Publicly available spontaneous reporting data for "Myocarditis" and
"Pericarditis" from EU/EEA and US following COVID-19 mRNA vaccines. Reports with
comorbidities or concurrent medication indicative of transplantation, HIV infection, or
cancer ("immunocompromised" population) were compared with each overall database
population.

Data extraction and synthesis: Two researchers extracted data. Spontaneously reported
events of myocarditis and pericarditis were presented for immunocompromised
populations for each data source, stratified by age, sex, dose, and time-to-onset (where
available). Seriousness of each event was determined according to the ICH E2A definition.
Proportional Reporting Ratio (PRR) was calculated.

Results: There were 178 reports of myocarditis and pericarditis amongst
immunocompromised individuals overall. Seriousness was comparable between the
immunocompromised and overall populations in both databases. No trends in age or sex
were observed amongst immunocompromised individuals. Most reports followed a
second vaccine dose and occurred within 14 days. The frequency of reporting was similar
to the wider population (PRR=1.36 [95% CI= 0.89-1.82] for VAERS population).

Conclusions: Myocarditis and pericarditis following COVID-19 vaccination are very rare,
and benefits of COVID-19 vaccination continue to outweigh any perceived risks. Reporting
rates of myocarditis and pericarditis were similar in immunocompromised individuals,
however defining characteristics differed compared to the whole population; therefore,
continued monitoring of adverse events following vaccination remains vital to understand
differences between population subgroups.

Strengths and Limitations of the Study

• This is the first study to bring together spontaneous reporting data from three
regions (Europe, the United States, and the United Kingdom) comparing
immunocompromised and immunocompetent populations adverse reactions
following COVID-19 mRNA vaccination

- Spontaneously reported adverse drug reaction data is known to be subject to underreporting and missing information, including information on comorbidities and concomitant medications.

- Further biases that may have influenced results, include differences in vaccination strategies between the three regions examined, differences in data collected via spontaneous reporting systems, and the fact that serious events are more likely to be reported.

- It is not possible to estimate incidence rates using spontaneous reporting data due to a lack of precise denominator data, i.e. the number of people who received the vaccine in the corresponding period.

Introduction

The COVID-19 mRNA vaccines developed by Pfizer/BioNTech and Moderna were the first mRNA vaccines approved for use and have been successfully implemented in the fight against the COVID-19 pandemic (1-3). They are successful both in terms of efficacy of the vaccines to elicit a protective immune response as well as the speed of development; this methodology for vaccination likely enables rapid modifications to fight any potential variants that may evade the current vaccinations in the future. This success does not come without concerns though, and careful monitoring in real-world studies are essential to ensure these new mRNA vaccinations are safe across the whole population. It is also important to determine whether multiple dosing has any adverse effects, especially if modified mRNA vaccinations may be used in the future to fight new COVID-19 variants or other viral infections.

Spontaneous reporting of adverse events enables a snapshot of real-world responses to be assessed, with the caveat that there is often under-reporting and missing data within these reports (4, 5). Reported adverse events have been reported across the world in response to COVID-19 mRNA vaccinations and several have been recognised within the product information guidance, including myocarditis, pericarditis, and myopericarditis (6, 7). Myocarditis and pericarditis are caused by inflammation of the myocardium pericardium leading to chest pain, shortness of breath, palpitations, cardiac failure, or abnormal heart rhythms (8, 9). In Europe, myocarditis and pericarditis have been reported at an excess of 26 to 57 events per million within one week of COVID-19 mRNA vaccination, while in the US it has been estimated that these events are reported at a rate of between one and 40.6 cases per million second doses of COVID-19 mRNA vaccines administered (10, 11). Within these populations, reporting rates were dependent on sex and age, with males under 30 years of age reporting myocarditis and pericarditis following COVID-19 mRNA vaccines at a higher rate than females under 30 and people aged 30 years and over (10, 11). The incidence of myocarditis and pericarditis following COVID-19 mRNA vaccination is likely to be higher considering the well-known under-reporting of spontaneous adverse reactions.

Due to potential differences in the immune response to vaccination between immunocompromised and 'healthy' individuals, we hypothesised that immunocompromised individuals might experience myocarditis or pericarditis at a higher

frequency, that characteristics (age and sex) of immunocompromised patients reporting
these events may differ, that clinical course may be more severe, and that duration of
symptoms may be longer compared with immune competent individuals. We therefore
aimed to determine the number of reports of myocarditis or pericarditis submitted by
immunocompromised patient subgroups and whether these reports follow a similar
reporting trend, in terms of age, sex, time-to-onset, and vaccine dose, compared with the
total population following mRNA vaccination.

Materials and Methods

Systematic searches of spontaneous reporting outputs of the European Union/European
Economic Area (EU/EEA; EudraVigilance) and the United States (US; Vaccine Adverse Event
Reporting System [VAERS] via CDC Wonder tool) were conducted to obtain data on
reported events of "myocarditis" and "pericarditis" amongst immunocompromised
individuals following COVID-19 mRNA vaccination (COVID-19 Vaccines Pfizer/BioNTech
[Comirnaty] and Moderna [Spikevax]). Searches of the VAERS and EudraVigilance
databases covered the period from the date of vaccine launch until 30 November 2021.

Meanwhile, systematic searches were carried out in the United Kingdom's Yellow Card
scheme's database of spontaneous reports to attain reports of "myocarditis" and
"pericarditis" following mRNA vaccination for immunocompromised individuals. These
searches were carried out by (Medicines and Healthcare Regulatory Agency (MHRA) staff
and supplied to us for analysis. The datalock point was 01 December 2021. Counts of
overall reports of myocarditis and pericarditis were obtained within a personal
communication from the MHRA. Further details regarding the overall population fatalities
were obtained from the 'Coronavirus vaccine - weekly summary of Yellow Card reporting'
(12). The datalock point for this data was 08 December 2021. Immunocompromised
individuals were defined as patients who were: transplant recipients, HIV/AIDs patients,
or cancer patients using chemotherapies. Counts of myocarditis and pericarditis reports
were tabulated for each immunocompromised subgroup.

Full details of these searches are provided in the Supplementary file.

The level of detail within reports differs between spontaneous reporting databases
depending on data collection forms used. In the VAERS database, it is possible to search
for comorbidities, while in EudraVigilance it is necessary to use concomitant
immunosuppressive treatments as a surrogate for immunosuppression. Therefore, in the
VAERS database we searched for reports of myocarditis or pericarditis following at least
one dose of COVID-19 mRNA vaccine (COVID-19 Vaccine Pfizer/BioNTech [Comirnaty] or
COVID-19 Moderna [Spikevax]), where a history of transplantation, was reported. To align
the data analysis both databases were searched for medications which could be used as a
surrogate marker for transplantation, HIV/AIDS, or cancer; these medications included
anti-rejection treatments, steroids, HIV/AIDS treatments, and anti-cancer therapeutics
approved in the US and EU (13-15). A full list of these medications is provided in the
Supplementary file. Methotrexate was included as a medication proxy for auto-immune
conditions and cancer, however due to its wide use in autoimmune disease methotrexate
was treated as a separate category. Age group and sex were obtained from each report
and presented in a flowchart. Where reported, time-to-onset and vaccine dose were

extracted and tabulated. Seriousness was obtained for each case, as defined in ICH Topic
E2A: Clinical Safety Data Management, namely myocarditis and pericarditis events which
were fatal, caused or prolonged hospitalisation (including surgery, where specified), or
were life-threatening (16). Two researchers independently searched the spontaneous
reporting databases and extracted data.

It is not possible to estimate incidence using spontaneously reported data due to inherent
limitations of spontaneous reporting systems (underreporting of events and the lack of a
denominator in the database). Instead, proportional reporting rates (PRR) were calculated
using the method described by Evans et al. (17). Unlike incidence rates which evaluates
the number of events relative to the total population exposed, PRR uses the total ADRs
reported following exposure to the vaccine in each subgroup as the denominator. A ratio
of reports of myocarditis and pericarditis from immunocompromised subgroups is then
compared with the total myocarditis and pericarditis reports from all vaccinees following
any dose of COVID-19 mRNA vaccination. PRR was calculated for the VAERS population
only, due to limitations of the search functions available for the EudraVigilance dataset.
168
Patient and Public Involvement

Patients and the public were not consulted during this study due to the data source used.
No identifiable information is included within the outputs of spontaneous reporting
systems.

Results

European Union/European Economic Area

There were 50 individual cases of myocarditis or pericarditis submitted to EudraVigilance
up to 30 November 2021 with EU/EEA origin, amongst patients with immunosuppression
as suggested by concomitant medications. Myocarditis was detailed in 19 (38.0%) of the
50 total reports, while pericarditis was reported for 29 (58.0%) cases. There were two
reports (4.0%) where both myocarditis and pericarditis were described. Most reports were
from patients in the 18-64 years age group (59.5% of 50 reports); 92.0% of reports
concerned adults aged 18 years or older (Figure 1). Twenty-nine of the 50 reports involved
a male patient (58.0%; Figure 1). In total, 82 medications of interest were reported within
the 50cases submitted to EudraVigilance up to 30 November 2021 (Table 1). Of all
concomitant medications investigated, cancer treatments were most commonly reported
(n=50 of 82 medications, 61.0%; Table 1). Ciclosporin was least frequently reported (n=1,
1.2%; Table 1).

Of the 50 reports from immunocompromised individuals, 38 (76.0%) met the criteria for a
'serious' event (defined as: event caused or prolonged hospitalisation, was life
threatening, or had a fatal outcome; Table 2). None of the myocarditis or pericarditis
events reported in immunocompromised subgroups of interest up to 30 November 2021
had a fatal outcome. In contrast, 75.78% of myocarditis or pericarditis events reported to
EudraVigilance in the population overall met the criteria for a serious case (n=4309 of 5681
cases reported following a COVID-19 mRNA vaccine, overall). Of these 5681 cases, 156
(2.7%) reported a fatal outcome.

 United States

Meanwhile in the VAERS spontaneous reporting system, there was a total of 3,062 reports
of myocarditis or pericarditis following mRNA vaccination (Pfizer or Moderna), of which
1.83% (n=57; Figure 2) were from immunocompromised individuals. These spontaneous
reports of myocarditis or pericarditis in immunocompromised individuals differed in their
gender and age distribution compared to the whole population with myocarditis or
pericarditis (18). The whole population had a bias of younger males experiencing
myocarditis or pericarditis following COVID-19 mRNA vaccinations (18), whereas from the
immunocompromised population 52.6% of these events occurred in males and 50.9%
were under 60 years of age. Thus, this could indicate a broadening in those susceptible to
myocarditis or pericarditis in immunocompromised individuals. Splitting the analysis of
immunocompromised individuals into transplant recipients, medically induced
immunosuppression using methotrexate, HIV, and cancer is indicated in Figure 2. Within
these four subsets we investigated whether there were patterns in time-to-onset or
vaccination dose for reported myocarditis or pericarditis events (Table 3). Predominately
events were reported after the second mRNA vaccination (mean 51.8%; range 33.3 –
61.3% within immunocompromised subgroups), while 8.9% of events (range 0 – 16.1%
within immunocompromised subgroups) were reported following the third vaccination
dose (Table 3). Approximately 70% of reported events occurred within 14 days of
vaccination (n=39; range 44.4 – 100% within immunocompromised subgroups; Table 3).
Therefore, this is suggestive of a potential causal effect due to the rapid onset of symptoms
following exposure to a COVID-19 mRNA vaccine. The seriousness of each event, (resulting
in hospitalisation, surgery, or fatality) was assessed and recorded in Table 2, with 41.1%
(n=23) of the 56 reports of myocarditis or pericarditis from immunocompromised
subgroups meeting the criteria for 'serious.' Surgery was required for three individuals,
and one fatality was recorded. The fatal event occurred in a female undergoing cancer
therapy, eight days after receiving the first dose of COVID-19 Vaccine Moderna. Cause of
death was not specified within the report, however an autopsy demonstrated systemic
inflammatory reaction, which affected primarily the small blood vessels of the brain with
leptomeninges, heart, lungs, and liver also affected. Generalised systemic tissue
inflammation caused diffuse intravascular inflammatory microthrombi and haemorrhagic
myocarditis. In comparison, for all myocarditis and pericarditis reports 63.4% were
classified as serious, this includes immunocompromised as well as immune-competent
individuals.

To determine whether these events were reported at higher levels in
immunocompromised compared to immune-competent (or unspecified) individuals a PRR
was calculated. This was only possible in the VAERS dataset, due to data limitations in the
EudraVigilance and Yellow Card datasets. In the VAERS population, the reporting rate of
myocarditis and pericarditis was slightly higher for immunocompromised patients
(transplant recipients, HIV/AIDS patients, and cancer patients) compared with immune
competent individuals (PRR=1.36 [95% CI: 0.89-1.82]). However, no statistical differences
were observed. It should be noted that PRR are not the same as incidence rates. Data on
duration of symptoms was not available for either database examined.

United Kingdom

In total, 1009 reports of myocarditis and pericarditis following either COVID-19 mRNA
vaccination had been submitted to the Yellow Card scheme up to 01 December 2021 (12).

As of 08 December 2021, there had been three reported to have a fatal outcome; all three
fatal events were in people who had received Pfizer/BioNTech (12). The reporting rate for
Pfizer/BioNTech was 11 cases of myocarditis reported per million, and eight cases of
pericarditis reported per million first or second vaccine doses. For Moderna, there were
39 reports of myocarditis doses and 22 reports of pericarditis per million first and second
doses of the vaccine administered (12). Reporting rates were highest for the 19-29 years
age group for both COVID-19 mRNA vaccines, with a trend for decreased reporting in older
age groups in the population overall (12).

Amongst immunocompromised individuals overall, there were 72 cases of myocarditis,
pericarditis, or myopericarditis reported to the Yellow Card scheme up to 01 December
2021 (Figure 3). Therefore, of all myocarditis or pericarditis reports recorded in the UK,
7.1% were from immunocompromised individuals. The majority of myocarditis and
pericarditis events were from people aged <65 years, similar to the overall population who
had reported events in the UK, whereas the male dominance of events seen in the whole
population (74.9% of myocarditis and pericarditis were from males) (18) was not seen in
the immunocompromised, here 51.4% of reports were from females (n=37; Figure 3).
Further classification of these events reported in the UK are detailed in Table 4. One event
was excluded from the analysis as it was not classified as myocarditis or pericarditis, rather
it described general cardiac issues following COVID-19 mRNA vaccination.

Myocarditis and pericarditis may occur more often in cancer patients following Pfizer
mRNA vaccination

Next, we determined whether myocarditis and pericarditis in the immunocompromised
subgroups, categorised as: transplant recipients, methotrexate-treated patients, HIV
patients or individuals on approved cancer therapeutics (please see supplementary file for
full medication lists) differed with the vaccines manufacturer used. This analysis was
undertaken using the EudraVigilance and VAERS datasets only, due to how the information
was reported from these systems allowed for stratification in this manner. Of the reports
in these two datasets Pfizer/BioNTech had a higher number of reports, although details on
total vaccines, and from which manufacturer, given in these discrete
immunocompromised populations is unknown, which may have impacted the higher
number of reports following Pfizer/BioNTech vaccine administration compared to
Moderna. Vaccine roll out, vaccine interval period and demographics of recipients of each
vaccine in each region were unknown and may have differed, which may have led to higher
reports following Pfizer/BioNTech administration compared to Moderna. This is
inconsistent with the overall reporting population where higher reporting rates from
Moderna were seen, potentially due to higher amounts of mRNA contained with Moderna
vaccines compared to Pfizer/BioNTech (100 µg vs 30 µg, respectively) (19, 20). To
determine whether the number of reports from each immunocompromised subgroup
differed following each vaccine type, the percentage of reports was calculated using the
total number of myocarditis and pericarditis reports from each vaccine type as the
denominator. Following Pfizer/BioNTech vaccine administration 57.8% of reports of
myocarditis and pericarditis were received from individuals on cancer therapeutics,
whereas a lower percentage of reports was received following Moderna vaccination (Table
5). This data is suggestive that potentially different immunocompromised conditions may
require careful consideration as to the type of mRNA COVID-19 vaccines given.

Myocarditis and pericarditis events are not restricted to mRNA based COVID-19 vaccines

Vaccine-associated myocarditis and pericarditis following COVID-19 vaccination is not only restricted to the use of mRNA-based vaccinations. Reports of myocarditis and pericarditis have been reported following adenovirus vector COVID-19 vaccines, suggesting it may not be the mRNA component of vaccines which trigger this response but the immune response or elements of SARS-CoV-2 itself. In the UK, 385 events of myocarditis and pericarditis had been reported via the Yellow Card scheme following administration of the AstraZeneca adenovirus vector COVID-19 vaccine, up to 15 December 2021 (12), which includes immunocompromised as well as immunocompetent populations. Meanwhile a total of 348 events have been reported to EudraVigilance following vaccination with AstraZeneca or Janssen COVID-19 vaccines (Table 6) and 141 events following Janssen vaccination have been reported to VAERS (Table 6). We were able to stratify the events reported to EudraVigilance and VAERS into those reported by immunocompromised individuals and immunocompetent and calculated the percentage of total events from each dataset that were associated with these two population groups (Table 6). The number of myocarditis and pericarditis events is much lower following viral vector vaccines, although direct comparison is not advisable due to differing total number of vaccinees receiving each type of vaccine. Percentages of reports from immunocompromised individuals are comparable for mRNA-based vaccines and adenovirus vector vaccines, with 95% confidence intervals which overlap (Table 6).

Mechanisms of myocarditis and pericarditis following mRNA COVID-19 vaccination

The mechanisms for myocarditis or pericarditis following COVID-19 mRNA vaccination are not yet fully understood. It has not yet been determined whether it is the mRNA element itself or the 'self' generated COVID-19 spike protein from the mRNA message within the vaccines or the resultant immune response, which cardiac tissues are sensitive to.

Following infection or vaccination, the adaptive immune system is activated. Adaptive immunity involves lymphocytes, particularly B-cells and certain T cells, that bind and recognise the foreign antigen. Upon first infection, or vaccination, the pathogen is bound by naïve B cells via the B cell receptor (BCR) or processed by antigen presenting cells (APCs) into smaller fragments, known as antigens. In order to mount an appropriate immune response, B cells will undergo differentiation and maturation within the lymph nodes in the germinal centre reaction (Figure 4). The germinal centre reaction results in the generation of high affinity, high avidity BCRs for the antigen and leads to the production of antibody producing/secreting plasma B cells and memory B cells (Figure 4). Memory B cells will retain the ability to recognise this antigen after the infection has been cleared from the body and is able to rapidly produce plasma B cells and antibodies should the body encounter the pathogen again, rapidly eliminating a second challenge of infection. Simultaneously, T cells will undergo maturation in the thymus in the presence of foreign antigen presented by APCs and through the process of positive and negative selection results in deletion of T cells that bind with high avidity to 'self' molecules and promotes expansion of T cells that bind to the foreign antigen. This process of positive and negative selection also gives rise to immune tolerance where there is some cross-over in recognition

333 of self-antigens (21). This immune-tolerance process may give rise to T cells that are
334 reactive to self-antigens, in particular heart auto-reactivity (22), that could lead to
335 myocarditis and pericarditis.

336 There are multiple hypotheses suggested by Das et al (23) that may explain the mechanism
337 of myocarditis and pericarditis in response to the COVID-19 mRNA vaccines, including;

1. *"mRNA vaccines might generate very high antibody response producing a response similar to multisystem inflammatory syndrome in children (MIS-C) that is associated with COVID infection;*
2. *induction of anti-idiotype cross-reactive antibody-mediated cytokine expression in the myocardium, resulting in aberrant apoptosis and inflammation,*
3. *mRNA vaccines can induce a non-specific innate immune response or a molecular mimicry mechanism may occur, or*
4. *the mRNA itself may be a potent immunogen producing an adjuvant effect."*

The advantage of mRNA vaccines is their ability to elicit a greater memory response
compared to adenovirus vector vaccines (24). The longevity of mRNA vaccines (as
evidenced by the persistence of the mRNA and mRNA translation APCs/dendritic cells
(DCs) at the injection site and draining lymph nodes) for up to 10 days may enable fine-
tuning of the immune responses due to somatic hypermutation, increasing the affinity of
the BCR to the immunogen, as well as enabling memory B cell maturation (25) (Figure 4).
The ability of mRNA vaccines to produce the immunogen of interest via mRNA translation
from within APCs was thought to mimic viral infection, which would elicit a CD8+ cytotoxic
T cell response but this is not seen with the COVID-19 mRNA vaccines or in mRNA vaccine
trials against rabies virus glycoprotein (RABV-G) or Influenza (H1N1) (25). These mRNA
vaccines have demonstrated that, in non-human primates, CD4+ helper T cell responses
are elicited (26, 27).

The role of CD4+ T cells in myocarditis has been reviewed by Vdovenko and Eriksson that
indicates that CD4+ T cells are the main drivers of heart-specific autoimmunity (28).
Therefore, the CD4+ T cell response following mRNA vaccines may trigger myocarditis.
CD4+ T cells differentiate into effector or regulatory T cells (T_{eff} or T_{reg}, respectively). T_{regs}
are vital in immune tolerance to suppress autoimmune T_{eff} cells. Gender differences in
circulating T_{regs} has been linked with gender differences in myocarditis (22). Thus the
involvement in CD4+ T cells in myocarditis development may indicate that autoimmune
responses may occur following mRNA vaccination, via induction of CD4+ T cell expression
and may point to the observed differences in myocarditis incidence between males and
females following vaccination (18).

Whether the mRNA within the vaccine itself is immunogenic will likely depend on multiple
variables within the mRNA sequence. The COVID-19 mRNA vaccines deliver a single
stranded mRNA (ssRNA) encoding the spike protein, with modified nucleotides. The
modified N^1-methyl-psuedouridine are known to dampen innate immune responses, while
increasing the efficiency of translation *in vivo* (27). As ssRNA is produced by all cells within
the body, ssRNA would be recognised as 'self' and would not trigger an immune response.
Double-stranded RNA (dsRNA) is generally recognised by the cell as viral or is triggered for
degradation via the RNA-induced silencing complex (RISC), the cells' innate ability to
modify protein expression by degradation of mRNA (29). Thus the sequence of the ssRNA

in the mRNA vaccine will determine the likelihood of complementarity (to itself, other
mRNAs or microRNAs) to generate dsRNA which could then trigger immune responses via
Toll-like Receptors (TLRs) (30) as well as alter mRNA translation mechanisms (29). Further
investigation is needed to determine whether the mRNA sequence is complementary to
any 'self' mRNA or microRNAs, as this could provide a greater understanding on why
certain organs may be preferentially targeted in response to COVID-19 mRNA vaccination.
The ability for mRNA vaccines to produce binding and neutralising antibodies in all
participants in phase I/II trials (24) demonstrates the ability for these vaccines to activate
the immune system similar to viral infection but with high antibody titres (31). Although it
should be noted that immunocompromised individuals elicit a reduced antibody response
following vaccination (32, 33). Thus, these highly immunogenic mRNA vaccines are
activating the B and T lymphocytes, with the potential that heart-specific autoreactive
CD4+ T cells may also be activated (or not adequately suppressed correctly via immune-
tolerance interactions of $T_{reg's}$ with T_{eff} cells) potentially leading to reporting of myocarditis
and pericarditis (4, 34, 35).

Discussion and conclusions

Based on the results of spontaneous reporting analyses, there was limited evidence
supporting our hypothesis that frequency or seriousness of the myocarditis and
pericarditis events reported to spontaneous reporting systems was substantially different
for immunocompromised people compared with the reporting population as a whole. In
the overall database populations myocarditis and pericarditis seemed to more frequently
affect younger males, however the characteristics of those susceptible may have
broadened in the immunocompromised population in terms of age and sex; therefore, risk
factors for these events are less clear within the immunocompromised population.

Recent reporting of myocarditis and pericarditis in immunocompromised individuals
(people on immunosuppressant medications following transplantation, treatment of
cancer, or people with HIV infection) raises an important question into how the immune
system is responding to mRNA vaccination in these individuals, and whether alternative
COVID-19 vaccinations should be considered. Given the current understanding that COVID-
19 mRNA vaccines elicit a CD4+ T cell response and the fact that immunocompromised
patients have inhibited B and T lymphocyte activity, immune suppression could be a factor
which increases the risk of adverse events following COVID-19 mRNA vaccination. In
particular, myocarditis and pericarditis following COVID-19 mRNA vaccination may be due
to the involvement of CD4+ T cells. Although HIV patients have demonstrated a similar
immune response to vaccination compared with healthy adults, other
immunocompromised patient subgroups, including those with solid or haematological
cancers, solid organ or bone marrow transplantation, and other immunosuppressive
conditions, have been shown to generate a lower immune response to COVID-19
vaccination compared with healthy controls (36-39). Therefore, it is possible that
immunosuppression due to medication or a medical condition may have an impact on the
safety and efficacy of mRNA vaccines against SARS-CoV-2 and other conditions.

Our analysis has not demonstrated a higher frequency of reports of myocarditis and
pericarditis amongst the immunocompromised patient subgroups examined (PRR for the
VAERS population=1.36 [95% CI: 0.89-1.82]), although the clinical course may be different
for these patients compared with immune-competent individuals and requires further
monitoring. When the signal first emerged, myocarditis and pericarditis following COVID-

19 mRNA vaccination were considered mild conditions of short duration which mostly
affected younger males (18, 40-43). Our analysis of reports from immunocompromised
individuals resulted in this sex distribution being less apparent for immunocompromised
individuals compared with that seen in the general population (18, 41, 42). Amongst
immunocompromised individuals, males accounted for 52.6% of reported events of
myocarditis and pericarditis submitted to all three datasets combined, thus a slight
decrease in male predominance for this effect. Overall, 59.7% cases of myocarditis and
pericarditis reported from immunocompromised individuals were under the age of 64
years. Furthermore, many of the reported events submitted to EudraVigilance and VAERS
amongst immunocompromised subgroups met the criteria for a serious case (77.6% of 49
reports submitted to EudraVigilance, and 68.4% of 57 reports to VAERS). Meanwhile,
76.8% of myocarditis or pericarditis cases reported after COVID-19 mRNA vaccines to
EudraVigilance from the population as a whole met the criteria for a serious case, while
63.4% of all cases reported to VAERS were serious in nature. For the VAERS population,
time-to-onset was consistent with previous suggestions that these events occur within 14
days of vaccination, with approximately 70% of events reported to occur within 14 days of
receiving a COVID-19 mRNA vaccine (40, 44). Consistencies in the frequency of events
reported and the seriousness of cases for immunocompromised people within the data
sources utilised suggests results may be generalisable to other populations in which mRNA
vaccines are used. Interestingly, in comparison to the US data which demonstrated that
50% of events in immunocompromised occurred following the second dose of an mRNA
vaccination the UK data demonstrates a less apparent separation between doses one and
two (31% vs 39.4%), while 23.9% of events occurred following the third dose.

Spontaneous adverse events reported to the Yellow Card scheme in the UK following a
COVID-19 mRNA vaccination resulted in higher reporting of myocarditis and pericarditis in
immunocompromised individuals as a proportion of the total myocarditis and pericarditis
reports compared to immunocompromised individuals in the EU and US databases (7.1%
vs 0.84 and 1.86%, respectively). There are many potential reasons for these differences
including different reporting systems that may allow for better collection of comorbidities
or concomitant medication. Spontaneously reported data from the population as a whole
indicated myocarditis and pericarditis occurred predominately in young males. Results
from the UK are consistent with those from the EU and US, where data demonstrated a
broadening of these susceptible characteristics in immunocompromised individuals. Up to
15 December 2021, 38.4% of reports of myocarditis and pericarditis following COVID-19
mRNA vaccination were from females in the UK; therefore in the immunocompromised
population there had been a 1.37-fold higher frequency of myocarditis and pericarditis
reports from immunocompromised females (12). The majority of reports occurred
following the second dose (39.4%) in the UK which was consistent with reports from the
US (54.4% reported following a second dose), although this interpretation should be taken
with caution given that the third dose (booster) programme is still ongoing in the UK, with
more data likely to be reported in the coming weeks and months. However,
immunocompromised people were prioritised to receive their third (booster) dose when
the UK booster vaccination programme started in September 2021, therefore it is expected
that the majority of people within this subpopulation would have received their third dose
by the datalock point of 01 December 2021 (45, 46).

The use of spontaneous reporting systems has some limitations which are important to
recognise, including the possibility that these data are underestimated due to

underreporting of events and missing information on comorbidities and concurrent
medications within individual case reports (47) (5, 48). Additionally, concomitant
medication was not commonly reported; medications for cancer and HIV/AIDS may be
used for other conditions and may therefore inaccurately represent the number of
immunocompromised patients within the dataset. However, for the EudraVigilance
population the use of a proxy measure was the only method for identifying reports from
people in these patient subgroups. Furthermore, not all immunosuppressive treatments
were examined in this analysis, but a comprehensive list of immunosuppressants should
be included in future studies. It will therefore become increasingly important to monitor
the occurrence and clinical course of myocarditis and pericarditis amongst
immunocompromised patients as booster vaccination programmes progress. While
COVID-19 vaccination programmes continue to progress to widespread roll-out of third
and subsequent booster doses, more immunocompromised individuals will become
exposed to COVID-19 mRNA vaccines and some for the first time, particularly in countries
where adenovirus vector COVID-19 vaccines were preferentially given to older members
of the population and those at higher clinical risk of severe COVID-19 outcomes (many of
whom were immunocompromised) for their first two doses. Current data indicates that
three doses of mRNA vaccines are safe, which included immunocompromised individuals
in the population cohort (49). Consideration should be given to the risk of myocarditis and
pericarditis in vaccine recipients who demonstrate low- or non-response to COVID-19
vaccination where additional vaccine doses are warranted; while immunocompromised
patient subgroups have generally been shown to elicit sufficient immune response to
COVID-19 vaccination, many of those who do respond poorly may be
immunocompromised, including cancer patients or transplant recipients (50). Further
studies are required to better understand the occurrence of myocarditis and pericarditis
following additional mRNA COVID-19 vaccine doses in immunocompromised individuals
and for those who have demonstrated limited response to vaccination.

It should also be noted that undiagnosed COVID-19 infection may be an underlying risk
factor for myocarditis or pericarditis rather than the vaccine. In the US, it has been
demonstrated that risk of cardiac complications is higher following SARS-CoV-2 infection
than mRNA vaccination in all age groups for both males and females (51). In the UK, SARS-
CoV-2 infection has been found to increase risk of hospitalisation or death from cardiac
complications, including myocarditis and pericarditis, and produce a higher number of
excess events due to exposure compared with mRNA vaccination (52). Epidemiological
studies are warranted to determine whether a similar pattern is seen amongst
immunocompromised individuals. Within the data analysed from spontaneous reporting
systems for the immunocompromised group, only one case of pericarditis following Pfizer
vaccination was identified as also being infected with COVID-19. As immunocompromised
individuals accounted for less than 10% of all reports of myocarditis and pericarditis in
response to vaccination across the three regions analysed, detecting cases where COVID-
19 infection may also have contributed to the reaction will be a small proportion of this
limited number of reports. Thus, levels of detecting in this method of analysis may be
unable to identify these potentially rare events in this population. It is worth noting that
immunocompromised individuals may also be less likely to become infected if they are
shielding or maintaining stricter social distancing measures. This raises the very interesting
question of whether vaccination associated myocarditis and pericarditis is a consequence
of the immune response elicited to generate a robust response that also occurs following
infection. Therefore is vaccination preventing these individuals suffering or reducing the
severity of myocarditis and pericarditis if they were exposed to the SARS-CoV-2 virus?

Based on current data, immunocompromised individuals reporting myocarditis or pericarditis differed in gender and age distribution compared to the whole population. As risk factors for myocarditis and pericarditis are less clear in the immunocompromised population, it will be important to continue monitoring the occurrence and clinical course of myocarditis and pericarditis in immunocompromised individuals following COVID-19 mRNA vaccines. Further monitoring of events in immunocompromised patients will be of particular importance if mRNA treatments and vaccines continue to be pursued for these conditions. If mRNA vaccines, and potentially other mRNA-based therapeutics, are linked with adverse events in immunocompromised individuals, this may alter their therapeutic potential, may alter treatment regimes, or may stratify patients into different treatment options. It is worth noting that autoimmune disorders, such as arthritis and systemic lupus, have been linked to pericarditis as well as some immunosuppressive medications, including methotrexate (53). Thus, careful evaluation needs to be undertaken, taking into consideration the baseline characteristics of this population to accurately determine the reporting rates related to mRNA vaccination.

It should be noted that our results are based on the best available, though limited, information. Results should be confirmed by quantitative data from formal pharmacoepidemiological studies, to allow accurate calculation of incident risk of myocarditis and pericarditis amongst immunocompromised patients compared with immune competent individuals. Further ongoing monitoring is needed to formally characterise the clinical course of myocarditis and pericarditis following mRNA vaccination amongst immunocompromised patients. It is important to stress that events of myocarditis and pericarditis following COVID-19 vaccination are very rare and the benefits of COVID-19 vaccination continue to outweigh any perceived risks.

In conclusion, myocarditis and pericarditis are very rare events following COVID-19 mRNA vaccination in immunocompromised individuals, and risk factors such as age and sex are less clear in immunocompromised individuals compared to the total population. Slight differences were observed in reporting frequency of these adverse events between the different immunocompromised populations and vaccines, thus continued monitoring may enhance stratification of patients in the future for the most appropriate vaccine type to use.

References

1.   FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use
Authorization for First COVID-19 Vaccine [press release]. 11 December 2020 2021.
2.   UK authorises Pfizer/BioNTech COVID-19 vaccine [press release]. 2 December
2020 2020.
3.   Dolgin E. The tangled history of mRNA vaccines. Nature. 2021;597(7876):318-24.
4.   European Medicines Agency. EudraVigilance - European Database of Suspected
Adverse Drug Reaction Reports. 2021.
5.   Vaccine Adverse Event Reporting System. Guide to Interpreting VAERS Data 2021
[Available from: https://vaers.hhs.gov/data/dataguide.html.
6.   BioNTech-Pfizer. Comirnaty concentrate for dispersion for injection COVID-19
mRNA Vaccine (nucleoside modified) 2021 [updated 22 July 2021. Available from:
https://www.medicines.org.uk/emc/product/12740/smpc.
7.   Medicines & Healthcare products Regulatory Agency. Summary of Product
Characteristics for COVID-19 Vaccine Moderna 2021 [updated 25 June. Available from:
https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-
moderna/information-for-healthcare-professionals-on-covid-19-vaccine-moderna.
8.   British Heart Foundation. Myocarditis 2019 [updated December 2019. Available
from: https://www.bhf.org.uk/informationsupport/conditions/myocarditis.
9.   British Heart Foundation. Pericarditis 2019 [updated December 2019. Available
from: https://www.bhf.org.uk/informationsupport/conditions/pericarditis.
10.   Meeting highlights from the Pharmacovigilance Risk Assessment Committee
(PRAC) 29 November - 2 December 2021 [press release]. 3 December 2021 2021.
11.   Gargano JW, Wallace M, Hadler SC, Langley G, Su JR, Oster ME, et al. Use of mRNA
COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from
the Advisory Committee on Immunization Practices - United States, June 2021. MMWR
Morbidity and mortality weekly report. 2021;70(27):977-82.
12.   Medicines & Healthcare products Regulatory Agency. Coronavirus vaccine - weekly
summary   of   Yellow   Card   reporting   2021   [Available   from:
https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-
reactions/coronavirus-vaccine-summary-of-yellow-card-reporting.
13.   National Cancer Institute. A to Z List of Cancer Drugs 2021 [Available from:
https://www.cancer.gov/about-cancer/treatment/drugs.
14.   Cancer Research UK. Cancer drugs A to Z list 2021 [Available from:
https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-
drugs/drugs.
15.   NAM. HIV treatment

A   to   Z   of   antiretroviral   medications   2021   [Available   from:
https://www.aidsmap.com/about-hiv/a-z-antiretroviral-medications.
16.   European Medicines Agency. ICH Topic E 2 A

Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. 1995
June. Report No.: CPMP/ICH/377/95.
17.   Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal
generation from spontaneous adverse drug reaction reports. Pharmacoepidemiology and
Drug Safety. 2001;10(6):483-6.
18.   Lane S, Yeomans A, Shakir S. Reports of myocarditis and pericarditis following
mRNA COVID-19 vaccines: A systematic review of spontaneously reported data from the
UK, Europe, and the US and of the literature. medRxiv. 2021:2021.09.09.21263342.
19.   European Medicines Agency. Spikevax (previously COVID-19 Vaccine Moderna):
EPAR - Product information. 2021.

20.   European Medicines Agency. Comirnaty: EPAR - Product Information. 2021.

21.   Griesemer AD, Sorenson EC, Hardy MA. The role of the thymus in tolerance.
Transplantation. 2010;90(5):465-74.

22.   Vdovenko D, Eriksson U. Regulatory Role of CD4(+) T Cells in Myocarditis. Journal
of immunology research. 2018;2018:4396351.

23.   Das BB, Moskowitz WB, Taylor MB, Palmer A. Myocarditis and Pericarditis
Following mRNA COVID-19 Vaccination: What Do We Know So Far? Children (Basel,
Switzerland). 2021;8(7).

24.   Centers for Disease Control and Prevention. Science Brief: SARS-CoV-2 Infection-
induced and Vaccine-induced Immunity 2021 [updated 29 October 2021. Available from:
https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/vaccine-induced-
immunity.html.

25.   Cagigi A, Loré K. Immune Responses Induced by mRNA Vaccination in Mice,
Monkeys and Humans. Vaccines (Basel). 2021;9(1).

26.   Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP, et al.
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl
J Med. 2020;383(16):1544-55.

27.   Vogel AB, Kanevsky I, Che Y, Swanson KA, Muik A, Vormehr M, et al. BNT162b
vaccines protect rhesus macaques from SARS-CoV-2. Nature. 2021;592(7853):283-9.

28.   Vdovenko D, Eriksson U. Regulatory Role of CD4+ T Cells in
Myocarditis. Journal of Immunology Research. 2018;2018:4396351.

29.   Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes:
mechanisms and biological targets. Cell. 2009;136(4):731-45.

30.   Manik M, Singh RK. Role of toll-like receptors in modulation of cytokine storm
signaling in SARS-CoV-2-induced COVID-19. Journal of medical virology. 2021.

31.   Walsh EE, Frenck RW, Jr., Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety
and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. The New England
journal of medicine. 2020;383(25):2439-50.

32.   Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three Doses of an
mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. The New England journal of
medicine. 2021;385(7):661-2.

33.   Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, et al.
Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer
Cell. 2021;39(8):1081-90 e2.

34.   Golpour A, Patriki D, Hanson PJ, McManus B, Heidecker B. Epidemiological Impact
of Myocarditis. J Clin Med. 2021;10(4):603.

35.   Medicines & Healthcare products Regulatory Agency. Coronavirus vaccine - weekly
summary of Yellow Card reporting 2021 [updated 19 November 2021. Available from:
https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-
reactions/coronavirus-vaccine-summary-of-yellow-card-reporting.

36.   Sanders JF, Bemelman FJ, Messchendorp AL, Baan CC, van Baarle D, van Binnendijk
R, et al. The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and
Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or
Living With a Kidney Transplant. Transplantation. 2021.

37.   Kearns P, Siebert, S., Willicombe, M., Gaskell, C., Kirkham, A., Pirrie, S., Bowden,
S., Magwaro, S., Hughes, A., Lim, Z., Dimitriadis, S., Murray, S.M., Marjot, T., Win, Z., Irwin,
S.L., Meacham, G., Richter, A.G., Kelleher, P., Satsangi, J., Miller, P., Rea, D., Cook, G.,
Turtle, L., Klenerman, P., Dunachie, S., Basu, N., de Silva, T.I., Thomas, D., Barnes, E.,
Goodyear, C.S., McInnes, I., . Examining the Immunological Effects of COVID-19
Vaccination in Patients with Conditions Potentially Leading to Diminished Immune

Response Capacity – The OCTAVE Trial. Available at SSRN: https://ssrn.com/abstract=3910058 or http://dx.doi.org/10.2139/ssrn.3910058. 2021.

38. Boyarsky BJ, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL, et al. Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. Jama. 2021;325(21):2204-6.

39. Rahav G, Lustig Y, Lavee J, Ohad B, Magen H, Hod T, et al. BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study. EClinicalMedicine. 2021;41.

40. Centers for Disease Prevention and Control. Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination 2021 [updated 12 November 2021. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myocarditis.html.

41. Woo W, Kim AY, Yon DK, Lee SW, Hwang J, Jacob L, et al. Clinical characteristics and prognostic factors of myocarditis associated with the mRNA COVID-19 vaccine. Journal of medical virology. 2021.

42. Li M, Yuan J, Lv G, Brown J, Jiang X, Lu ZK. Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types. Journal of personalized medicine. 2021;11(11).

43. Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, et al. Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. The New England journal of medicine. 2021.

44. Montgomery J, Ryan M, Engler R, Hoffman D, McClenathan B, Collins L, et al. Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. JAMA Cardiol. 2021;6(10):1202-6.

45. NHS England. NHS begins COVID-19 booster vaccination campaign 2021 [updated 16 September 2021. Available from: https://www.england.nhs.uk/2021/09/nhs-begins-covid-19-booster-vaccination-campaign/.

46. Department of Health and Social Care. JCVI statement regarding a COVID-19 booster vaccine programme for winter 2021 to 2022 2021 [updated 14 September 2021. Available from: https://www.gov.uk/government/publications/jcvi-statement-september-2021-covid-19-booster-vaccine-programme-for-winter-2021-to-2022/jcvi-statement-regarding-a-covid-19-booster-vaccine-programme-for-winter-2021-to-2022.

47. García CH, Pinheiro L, Maciá MÁ, Stroe R, Georgescu A, Dondera R, et al. Spontaneous Adverse Drug Reactions [Available from: https://www.ema.europa.eu/en/documents/report/spontaneous-adverse-drug-reactions-subgroup-report_en.pdf.

48. Hazell L, Shakir SA. Under-reporting of adverse drug reactions : a systematic review. Drug safety. 2006;29(5):385-96.

49. Niesen MJM, Pawlowski C, O'Horo JC, Challener DW, Silvert E, Donadio G, et al. Three doses of COVID-19 mRNA vaccination are safe based on adverse events reported in electronic health records. medRxiv. 2021:2021.11.05.21265961.

50. Parker EPK, Desai S, Marti M, Nohynek H, Kaslow DC, Kochhar S, et al. Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review. Lancet Glob Health. 2022;10(3):e326-e8.

51. Centers for Disease Control and Prevention. Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination - PCORnet, United States, January 2021 - January 2022 2022 [Available from: https://www.cdc.gov/mmwr/volumes/71/wr/mm7114e1.htm?s_cid=mm7114e1_w.

52. Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nature medicine. 2022;28(2):410-22.

53.   Jastrzebska M, Czok ME, Guzik P. Autoimmune diseases, their pharmacological
treatment and the cardiovascular system. Cardiology journal. 2013;20(6):569-76.

Figure 1: Tree diagram detailing the characteristics of vaccinees submitting spontaneous
reports of myocarditis and pericarditis to EudraVigilance for EU and EEA only, following
COVID-19 mRNA vaccines in immunocompromised individuals

Reports of myocarditis or pericarditis were searched in the EudraVigilance database
following COVID-19 mRNA vaccines, either Moderna (Spikevax) or Pfizer/BioNTech
(Comirnaty) (n=50 reports). The resultant reports were further assessed for individuals
that were likely to be immunosuppressed based on the following search terms (transplant
medications*, HIV/AIDS treatments, EU-approved cancer therapies). Concomitant
medications were used as a proxy for disease status.

‡Counts are not mutually exclusive; one report may contain multiple concomitant
medications from different categories.

*Where tacrolimus, mycophenolate mofetil, ciclosporin, or prednisolone were reported as
concomitant medications.

**Methotrexate was included as a potential transplant medication, however due to its
wide use in autoimmune disease this was listed independently of the treatments used as
a proxy for transplantation.

Figure 2: Tree diagram detailing the characteristics of spontaneous reports of
myocarditis and pericarditis on the VAERS database following COVID-19 mRNA vaccines
in immunocompromised individuals

Reports of myocarditis, pericarditis or myopericarditis were searched in the VAERS
database following COVID-19 mRNA vaccines, either Moderna or Pfizer BioNTech. The
resultant reports were further assessed for individuals that were likely to be
immunocompromised based on the following search terms (transplant, tacrolimus,
mycophenolate mofetil, methotrexate, prednisolone, ciclosporin). Transplant recipients
were assessed separately to immunocompromised individuals that received medication,
independent of disease setting.

* unspecified category , ** cancer defined by use of cancer approved medicines

Figure 3: Tree diagram detailing the characteristics of spontaneous reports of
myocarditis and pericarditis on the Yellow Card database following COVID-19 mRNA
vaccines in immunocompromised individuals (Yellow Card, UK)

Reports of myocarditis, pericarditis or myopericarditis from immunocompromised
individuals were searched in the Yellow Card scheme following COVID-19 mRNA vaccines,
either Moderna or Pfizer BioNTech. Data provided by MRHA, datalock 1st December 2021.
* n=3 unspecified, ** n=2 under 18 years. For age category n=5 unknown.

Figure 4: Schematic of the immune response to antigen

Antigen is part of a foreign/non-self pathogen and is presented by an antigen presenting
cell (APC) either following viral protein digestion and presentation on the major

histocompatibility complex (MHC) or via mRNA translation of the protein within the APC
then the protein is presented on the MHC. The non-self protein presented on the MHC is
recognised by B and T cells. This triggers a cascade of intracellular signalling responses and
leads to the maturation of the B cells, within the germinal centre of a lymph node. The
germinal centre reaction involves interactions with B cells, antigen and T cells; leading to
somatic hypermutation of the B cell receptor (BCR), generating a BCR that is better
adapted to recognise the antigen. The B cell then differentiates into memory B cells and
plasma B cells to release the antibodies into the general circulation to clear the body of
the infection.

Table 1: Concomitant medications within spontaneous reports of myocarditis and pericarditis submitted to EudraVigilance for the European Union and European Economic Area only, following COVID-19 mRNA vaccines

Reports of myocarditis or pericarditis were searched in the EudraVigilance database following COVID-19 mRNA vaccines, either COVID-19 Vaccine Moderna (Spikevax) or Pfizer/BioNTech (Comirnaty). Medications were used as a proxy for immunocompromised subgroups: transplant recipients (tacrolimus, mycophenolate mofetil, methotrexate, Prednisolone, ciclosporin and steroids [including prednisolone]), HIV infection, and patients undergoing cancer treatment.

	Tacrolimus	Mycophenolate mofetil	Methotrexate	Ciclosporin	Prednisolone	HIV treatments	Cancer treatments**	Total*
Comirnaty								
Myocarditis	1	2	5	0	6	1	14	**29**
Pericarditis	0	2	7	1	8	1	25	**44**
Myopericarditis	0	0	0	0	0	0	2	**2**
Spikevax								
Myocarditis	1	2	1	0	0	0	0	**4**
Pericarditis	0	0	1	0	1	0	1	**3**
Myopericarditis	0	0	0	0	0	0	0	**0**
Total*	2	6	14	1	15	2	42	**82**

*Reports may contain more than one concomitant medication, and/or more than one event
**Hydrocortisone excluded as no indications given within reports and the drug is commonly used to treat other conditions

Table 2: Breakdown of serious myocarditis and pericarditis events reported via EudraVigilance and VAERS

Reports of myocarditis, pericarditis or myopericarditis were searched in the VAERS database following COVID-19 mRNA vaccines, either Moderna or Pfizer/BioNTech. The resultant reports were further assessed for individuals that were likely to be immunocompromised based on the following search terms (transplant, medicinal immunosuppressant drugs; tacrolimus, mycophenolate mofetil, methotrexate, Prednisolone, ciclosporin and Steroids, HIV or approved cancer therapeutics). Serious events were determined as required hospitalisation, surgery or fatality as detailed in the comments box. Values indicate the events recorded and the percentage of the total events in each of the four characteristic categories with a 95% confidence interval.

Immunocompromised Characteristic	Serious Events EudraVigilance*			Serious events VAERS			Total		
	n	%‡ (95% CI)	Total reported in subgroup	n	%‡ (95% CI)	Total reported in subgroup	n	%‡ (95% CI)	Total reported in subgroup
Transplant	22	91.7 (73.0-99.0)	**24**	2	20.0 (2.5-55.6)	**10**	24	70.5 (52.5-84.9)	**34**
Methotrexate-treated patients	11	78.6 (49.2-95.3)	**14**	5	55.6 (21.2-86.3)	**9**	16	69.6 (47.1-86.8)	**23**
HIV	2	100	**2**	3	42.9 (9.9-81.6)	**7**	5	55.5 (21.2-86.3)	**9**
Cancer Therapeutics	32	65.3 (50.4-78.3)	**49**	13	41.9 (24.5-60.9)	**31**	45	56.3 (44.7-67.3)	**80**

CI = Confidence Interval
*Counts not mutually exclusive, multiple medications could be reported in the same case
‡Percentage of total reports within the EudraVigilance or VAERS database for that subgroup
NB: Serious event defined as: event caused or prolonged hospitalisation, required surgery, was life threatening, or was fatal

Table 3: Spontaneous reports of myocarditis and pericarditis on the VAERS database following COVID-19 mRNA vaccines in immunocompromised individuals subdivided into time to onset and vaccine dosage

Reports of myocarditis, pericarditis or myopericarditis were searched in the VAERS database following COVID-19 mRNA vaccines, either Moderna or Pfizer/BioNTech. The resultant reports were further assessed for individuals that were likely to be immunocompromised based on the following search terms (transplant, immunosuppressant drugs; tacrolimus, mycophenolate mofetil, methotrexate, Prednisolone, ciclosporin and Steroids, HIV or approved cancer therapeutics: https://www.cancer.gov/about-cancer/treatment/drugs). Values indicate the events recorded and as a percentage of the total in each of the four characteristic categories with 95% confidence intervals.

Reports to VAERS															
Immuno-compromised characteristic	Outcome			Vaccine dose								Time to Onset of Symptoms			
		n	% (95% CI)	Dose 1		Dose 2		Dose 3		Unknown dose		<14 days		>14 days	
				n	% (95% CI)	n	% (95% CI)	n	% (95% CI)	n	% (95% CI)	n	% (95% CI)	n	% (95% CI)
Transplant	Myocarditis	1	11.1 (0.3-48.2)	0	0.00	2	22.2 (2.8-60.0)	0	0.0	0	0.0	0	0.0	2	22.2 (2.8-60.0)
	Pericarditis	5	55.6 (21.2-86.3)	1	11.1 (0.3-48.2)	2	22.2 (2.8-60.0)	0	0.0	3	33.3	4	44.4 (13.7-78.8)	2	22.2 (2.8-60.0)
	Myopericarditis	3	33.3 (7.5-70.1)	1	11.1 (0.3-48.2)	1	11.1 (0.3-48.2)	0	0.0	0	0.0	1	11.1 (0.3-48.2)	1	11.1 (0.3-48.2)

		n	%	n	%	n	%	n	%	n	%	n	%	n	%
	Total	9	100.0	3	33.3 (7.5-70.7)	3	33.3 (7.5-70.7)	0	0.0	3	33.3 (7.5-70.7)	4	44.4 (13.7-78.8)	5	55.6 (21.2-86.3)
Methotrexate	Myocarditis	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	Pericarditis	8	88.9 (51.8-99.7)	4	44.4 (13.7-78.8)	4	44.4 (13.7-78.8)	0	0.0	0	0.0	6	66.7 (29.9-92.5)	1	11.1 (0.3-48.2)
	Myopericarditis	1	11.1 (0.3-48.2)	0	0.0	0	0.0	0	0.0	1	11.1 (0.3-48.2)	1	11.1 (0.3-48.2)	0	0.0
	Total	9	100.0	4	44.4 (13.7-78.8)	4	44.4 (13.7-78.8)	0	0.0	1	11.1 (0.3-48.2)	7	77.8 (40.0-97.2)	1	11.1 (0.3-48.2)
HIV	Myocarditis	2	28.6 (3.7-71.0)	1	14.3 (0.4-57.9)	1	14.3 (0.4-57.9)	0	0.0	0	0.0	2	28.6	0	0.0
	Pericarditis	4	57.1 (18.4-90.1)	3	42.9 (9.9-81.6)	1	14.3 (0.4-57.9)	0	0.0	0	0.0	4	57.1 (18.4-90.1)	0	0.0
	Myopericarditis	1	14.3 (0.4-57.9)	0	0.0	1	14.3 (0.4-57.9)	0	0.0	0	0.0	1	14.3 (0.4-57.9)	0	0.0
	Total	7	100.0	4	57.1 (18.4-90.1)	3	42.9 (9.9-81.6)	0	0.0	0	0.0	7	100.0	0	0.0

Cancer Therapeutics		n	%	n	%	n	%	n	%	n	%	n	%	n	%
Cancer Therapeutics	Myocarditis	10	32.3 (16.7-51.4)	2	6.5 (0.8-21.4)	6	19.4 (7.5-37.5)	1	3.2 (0.1-16.7)	1	3.2 (0.1-16.7)	8	25.8 (11.9-44.6)	2	6.5 (0.8-21.4)
	Pericarditis	17	54.8 (36.0-72.7)	4**	12.9 (3.6-29.8)	11	35.5 (19.2-54.6)	2	6.5 (0.8-21.4)	0	0.0	10**	32.3 (16.7-51.4)	7	22.6 (9.6-41.1)
	Myopericarditis	4	12.9 (3.6-29.8)	0	0.0	2	6.5 (0.8-21.4)	2	6.5 (0.8-21.4)	0	0.0	3	9.7 (2.0-25.8)	0	0.0
	Total	31	100.0	6	19.4 (7.5-37.5)	19	61.3 (42.2-78.2)	5	16.1 (5.5-33.7)	1	3.2 (0.1-16.7)	21	67.7 (48.6-83.3)	9	29.0 (14.2-48.0)
All	Total	56	100.0	17	28.1 (18.8-44.1)	31	55.4 (41.5-68.7)	5	8.9 (3.0-19.6)	5	8.9 (3.0-19.6)	39	69.6 (55.9-81.2)	15	26.8 (15.8-40.3)

* n=1, unspecified time to onset
**n=1, fatality
CI=Confidence Interval

Table 4: Spontaneous reports of myocarditis and pericarditis submitted to the Yellow Card Scheme in the UK following COVID-19 mRNA vaccines in immunocompromised individuals

Reports of myocarditis or pericarditis were searched in the Yellow Card scheme following COVID-19 mRNA vaccines, either COVID-19 Vaccine Moderna (Spikevax) or Pfizer/BioNTech (Comirnaty). Events were classified by vaccination dose and time to onset of symptoms. *n=4 missing information on time-to onset, **n=1 excluded due to not classification by myocarditis, pericarditis or myopericarditis.

	Reports to Yellow Card (UK)													
Outcome			**Vaccine Dose**								**Time to Onset of Symptoms**			
			Dose 1		**Dose 2**		**Dose 3**		**Unknown**		**<14 days**		**>14 days**	
	n	% (95% CI)	n	% (95% CI)	n	% (95% CI)	n	% (95% CI)	n	% (95% CI)	n	% (95% CI)	n	% (95% CI)
Myocarditis	30	42.3 (30.6-54.6)	13	18.3 (10.1-29.3)	11	15.5 (8.0-26.0)	5	7.0 (2.3-15.7)	1	1.4 (0.0-7.6)	19	26.8 (16.9-38.6)	8	11.3 (5.0-21.0)
Pericarditis	38	53.5 (41.3-65.5)	9	12.7 (6.0-22.7)	14	19.7 (11.2-30.9)	12	16.9 (9.0-27.7)	3	4.2 (0.9-11.9)	24	33.8 (23.0-46.0)	13	18.3 (10.1-29.3)
Myopericarditis	3	4.2 (0.9-11.9)	0	0	3	4.2 (0.9-11.9)	0	0	0	0	2	2.8 (0.3-9.8)	1	1.4 (0.0-7.6)
Total	71**	100	22	31.0 (20.5-43.1)	28	39.4 (28.0-51.7)	17	23.9 (14.6-35.5)	4	5.6 (1.6-13.8)	45	63.4 (51.1-74.5)	22	31.0 (20.5-43.1)

CI=Confidence Interval

Table 5: Myocarditis and pericarditis adverse events reported following Moderna or Pfizer/BioNTech mRNA vaccination stratified by immunocompromised sub-groups

Reports of myocarditis, pericarditis or myopericarditis were searched in the EudraVigilance and VAERS database following COVID-19 mRNA vaccines, either Moderna or Pfizer/BioNTech. The resultant reports were further assessed for individuals that were likely to be immunocompromised based on the following search terms (transplant, immunosuppressant drugs; tacrolimus, mycophenolate mofetil, methotrexate, Prednisolone, ciclosporin and Steroids, HIV or approved cancer therapeutics: https://www.cancer.gov/about-cancer/treatment/drugs). Values indicate the events reported from each vaccine manufacture within each immunocompromised category. Percentage of the total reports for each manufacture are calculated for each of the characteristic categories

Immunocompromised Characteristic	EudraVigilance		VAERS		Total				
	Pfizer/BioNTech	Moderna	Pfizer/BioNTech	Moderna	Pfizer/BioNTech			Moderna	
					n	% (95% CI)	n		% (95% CI)
Transplant	20	4	7	2	27	24.77 (17.00-33.96)	6		20.69 (7.99-39.72)
Methotrexate-treated patients	12	2	1	8	13	11.93 (6.51-19.53)	10		34.48 (17.94-54.33)
HIV	2	0	4	3	6	5.5 (2.05-11.60)	3		10.34 (2.19-27.35)
Cancer Therapeutics	41	1	22	9	63	57.8 (47.96-67.20)	10		34.48 (17.94-54.33)
Total	75	7	34	22	109	100	29		100
CI=Confidence Interval									

Table 6: Comparison of the number of myocarditis and pericarditis adverse events following the different COVID-19 vaccination types

Reports of myocarditis, pericarditis or myopericarditis were searched in the EudraVigilance and VAERS database following COVID-19 mRNA vaccines, either Moderna or Pfizer/BioNTech, and adenovirus vector vaccines (AstraZeneca or Janssen). Comparison was made between the immunocompromised group identified in our analysis and the overall reporting population to the EudraVigilance and VAERS databases for these vaccines.

		mRNA vaccines		Adenovirus vector vaccines	
		Events (n)	% (95% CI)*	Events (n)	% (95% CI)*
EudraVigilance	Immunocompromised	50	0.9 (0.7-1.2)	5	1.43 (0.47-3.32)
	Immunocompetent or unknown	5632	99.1 (98.8-99.3)	343	98.56 (96.68-99.53)
	Total	**5682**	100.0	**348**	100.0
VAERS	Immunocompromised	57	1.86 (1.41-2.40)	3	2.13 (0.44-6.09)
	Immunocompetent or unknown	3006	98.14 (97.60-98.59)	138	97.87 (93.91-99.56)
	Total	**3063**	100.0	**141**	100.0
*Percentage of total					

Declarations

Transparency statement

The manuscript's guarantor affirms that the manuscript is an honest, accurate, and transparent account of the study being reported, and that no important aspects of the study have been omitted.

Ethics approval

Ethics approval was not required.

Funding

No external funding was received for the preparation of this manuscript.

Conflicts of interest

All authors have completed the Unified Competing Interest form (available on request from the corresponding author) and declare: The Drug Safety Research Unit (DSRU) is a registered independent charity (No. 327206) associated with the University of Portsmouth. The DSRU receives donations and grants from pharmaceutical companies; however, the companies have no control over the conduct or publication of its studies. The DSRU has received grants to conduct unconditional studies on the Oxford/AstraZeneca COVID-19 vaccine and is in negotiations to receiving grants for conducting CPRD studies for Pfizer, Moderna, and Janssen COVID-19 vaccines. The DSRU has conducted benefit-risk studies on products for COVID-19, including remdesivir, lopinavir/ritonavir, chloroquine and hydroxychloroquine, and convalescent plasma. Professor Shakir is the principal investigator for an active surveillance study for the Oxford/AstraZeneca vaccine, but this assessment is unrelated to this study. Professor Shakir has been a member of Data Safety Monitoring Boards for Ipsen, Biogen, and Diurnal. None of these companies have any involvement with COVID-19 vaccines. Professor Shakir was invited by AstraZeneca to advise on the events of thrombosis with thrombocytopenia with the COVID-19 vaccine and to be a member of an advisory committee on a safety study of the Oxford/AstraZeneca vaccine in Europe. Samantha Lane and Alison Yeomans have no conflicts of interest with regard to this study.

Authors' contributions

SL and AY were responsible for data acquisition, analyses, and interpretation. All authors were responsible for study conception, drafting and reviewing the manuscript, and approval of the final version for publication.

Data sharing

No additional data are available.

Figure 1: Tree diagram detailing the characteristics of vaccinees submitting spontaneous reports of myocarditis and pericarditis to EudraVigilance for EU and EEA only, following COVID-19 mRNA vaccines in immunocompromised individuals

Reports of myocarditis or pericarditis were searched in the EudraVigilance database following COVID-19 mRNA vaccines, either Moderna (Spikevax) or Pfizer/BioNTech (Comirnaty) (N=48 reports). The resultant reports were further assessed for individuals that were likely to be immunosuppressed based on the following search terms (transplant medications*, HIV/AIDS treatments, EU-approved cancer therapies). Concomitant medications were used as a proxy for disease status.

‡Counts are not mutually exclusive; one report may contain multiple concomitant medications from different categories.
*Where tacrolimus, mycophenolate mofetil, ciclosporin, or prednisolone were reported as concomitant medications.
**Methotrexate was included as a potential transplant medication, however due to its wide use in autoimmune disease this was listed independently of the treatments used as a proxy for transplantation.

Figure 2: Tree diagram detailing the characteristics of spontaneous reports of myocarditis and pericarditis on the VAERS database following COVID-19 mRNA vaccines in immunocompromised individuals

Reports of myocarditis, pericarditis or myopericarditis were searched in the VAERS database following COVID-19 mRNA vaccines, either Moderna or Pfizer BioNTech. The resultant reports were further assessed for individuals that were likely to be immunocompromised based on the following search terms (transplant, tacrolimus, mycophenolate mofetil, methotrexate, prednisolone, ciclosporin). Transplant recipients were assessed separately to immunocompromised individuals that received medication, independent of disease setting.

* unspecified category , ** cancer defined by use of cancer approved medicines

Figure 3: Tree diagram detailing the characteristics of spontaneous reports of myocarditis and pericarditis on the Yellow Card database following COVID-19 mRNA vaccines in immunocompromised individuals (Yellow Card, UK)

Reports of myocarditis, pericarditis or myopericarditis from immunocompromised individuals were searched in the Yellow Card scheme following COVID-19 mRNA vaccines, either Moderna or Pfizer BioNTech. Data provided by MRHA, datalock 1st December 2021. * n=3 unspecified, ** n=2 under 18 years. For age category n=5 unknown.

Figure 4: Schematic of the immune response to antigen

Antigen is part of a foreign/non-self pathogen and is presented by an antigen presenting cell (APC) either following viral protein digestion and presentation on the major histocompatibility complex (MHC) or via mRNA translation of the protein within the APC then the protein is presented on the MHC. The non-self protein presented on the MHC is recognised by B and T cells. This triggers a cascade of intracellular signalling responses and leads to the maturation of the B cells, within the germinal centre of a lymph node. The germinal centre reaction involves interactions with B cells, antigen and T cells; leading to somatic hypermutation of the B cell receptor (BCR), generating a BCR that is better adapted to recognise the antigen. The B cell then differentiates into memory B cells plasma B cells to release the antibodies into the general circulation to clear the body of the infection.